Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Neuroblastoma: The Way Ahead

22.06.2007
Future directions for treatment of the childhood cancer Neuroblastoma, and a detailed analysis of current regimens, are included in a Seminar in this week’s edition of The Lancet.

Plans for the development of an International Neuroblastoma Risk Group (INRG) classification system, to develop a consensus to permit comparisons of outcomes of neuroblastoma patients worldwide, are also included in the Seminar, authored by Dr John Maris, Children’s Hospital of Philadelphia, USA, and colleagues. The INRG is currently analysing data obtained from 11,054 patients treated in Europe, Japan, USA, Canada, and Australia between 1974 and 2002 so that this international classification system can be created.

Neuroblastoma is a cancer of the sympathetic nervous system - the nerve network that regulates the “fight or flight” response to the environment. When solid tumours form, which can take the form of a lump or mass, they commonly begin in one of the adrenal glands, though they can also develop in nerve tissues in the neck, chest, abdomen, or pelvis.

It is the most common solid extracranial cancer in childhood, and represents more than 7% of all childhood malignant cancers and 15% of all childhood cancer deaths. It is remarkable for its broad spectrum of clinical behaviour. Likelihood of cure varies widely according to age at diagnosis, extent of disease, and tumour biology.

The authors say: “Although substantial improvement in outcome of certain well-defined subsets of patients has been observed during the past few decades, the outcome for children with a high-risk clinical phenotype has improved only modestly, with long-term survival still less than 40%.”

There are three main sets of presenting signs and symptoms, categorised as localised tumours, metastatic disease, and 4S disease. Around 40% of patients present with localised tumours which can vary in size and occur anywhere in the sympathetic nervous system. In certain locations these tumours can cause compression of the spinal cord and resulting motor weakness in 5-15% of patients. Around half of patients present with metastatic disease, which often involves multiple tumour burdens which can make patients quite ill. This type of tumour can also metastatise bony orbits, and can lead to symptoms such as raccoon eyes (periorbital bruises). 4S disease occurs in only 5% of patients with neuroblastoma – and presents as small localised primary tumours with secondary tumours in liver, skin or bone marrow that almost always spontaneously regress.

The treatment methods used in neuroblastoma management include surgery, chemotherapy, radiotherapy, and biotherapy, as well as observation alone in carefully selected circumstances.

But new approaches to relapsed disease for patients with high-risk neuroblastoma have developed in recent years. These include cytotoxic agents, targeted delivery of radionuclides, immunotherapy, retinoids, angiogenesis inhibitors, and tyrosine kinase inhibitors.

The authors conclude that improvements in understanding of the genomic alterations associated with tumour and behaviour and patient outcome have moved the goal of precise prognosis closer.

They say: “Improved understanding of normal neurodevelopment of the sympathicoadrenal stem will help us identify the key mutational events that initiate neuroblastoma tumorigenesis. Defining these events, as well as those that reliably predict for the acquisition of a high-risk phenotype, might ultimately direct us to the key pathways that can be exploited therapeutically.”

Tony Kirby | alfa
Further information:
http://www.thelancet.com/webfiles/images/clusters/thelancet/press_office/Seminar.pdf

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>